Caplacizumab is a monoclonal antibody fragment that inhibits the interaction between von Willebrand factor and platelets, used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Caplacizumab
Generic Name/API:Caplacizumab-yhdp
Packaging:1 mg as a white lyophilized powder in a single-dose vial
Storage:Store refrigerated at 2°C to 8°C (36°F to 46°F)
Dosage:For dosage information, please check the General Information section.
Strength:11 mg as a white lyophilized powder in a single-dose vial
Indication:Caplacizumab offers targeted inhibition of interaction between vWF and platelet, providing rapid platelet count normalization and reducing acquired thrombotic thrombocytopenic purpura (aTTP) recurrence.
CABLIVI (caplacizumab-yhdp) is a targeted antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP) in adults. It works by binding to the A1-domain of the von Willebrand factor (vWF), preventing its interaction with platelets. This action reduces abnormal platelet adhesion and consumption. CABLIVI is used alongside plasma exchange and immunosuppressive therapy.
STRENGTH:
For injection: 11 mg as a white lyophilized powder in a single-dose vial.
DOSAGE:
Caplacizumab should be administered upon initiation of plasma exchange therapy. The recommended dose of caplacizumab is as follows:
- First day of treatment: 11 mg bolus intravenous injection at least 15 minutes prior to plasma exchange followed by an 11 mg subcutaneous injection after completion of plasma exchange on day 1.
- Subsequent days of treatment during daily plasma exchange: 11 mg subcutaneous injection once daily following plasma exchange.
- Treatment after plasma exchange period: 11 mg subcutaneous injection once daily continuing for 30 days following the last daily plasma exchange. If after the initial treatment course, sign(s) of persistent underlying disease such as suppressed ADAMTS13 activity levels remain present, treatment may be extended for a maximum of 28 days.
Treatment with caplacizumab is to be continued if the patient experiences more than 2 recurrences of aTTP, during treatment itself. Avoid concomitant use of antiplatelet agents or anticoagulants.
SIDE EFFECTS:
Hemorrhage is a primary adverse reaction of caplacizumab treatment.
STORAGE :
Store refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze. Unopened vials may be stored in the original carton at room temperature up to 30°C (86°F) for a single period of up to 2 months. Do not return caplacizumab to the refrigerator after it has been stored at room temperature.
- Hemorrhage: (occured in 58% patients under caplacizumab treatment) Caplacizumab increases the risk of serious and potentially fatal bleeding, especially in patients with underlying coagulopathies such as hemophilia or other coagulation factor deficiencies.
- Concomitant use of antiplatelet agents or anticoagulants should be avoided. If clinically significant bleeding occurs, treatment should be interrupted. Caplacizumab should be withheld at least 7 days prior to elective surgeries, dental procedures, or other invasive interventions.
- If rapid correction of hemostasis is needed, von Willebrand factor concentrate may be administered. In the event of emergency surgery, this may also be used to manage bleeding. If caplacizumab is restarted after surgery, patients should be closely monitored for signs of bleeding.
FAQ
What is caplacizumab used for?
Caplacizumab is used for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, in combination with plasma exchange and immunosuppressive therapy.
What is caplacizumab?
Caplacizumab is a monoclonal antibody fragment that inhibits the interaction between von Willebrand factor and platelets, used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
What are the common side effects of caplacizumab use?
The primary side effect of treatment with Caplacizumab is hemorrhage.
Can Caplacizumab be used in specific populations (pregnant, breastfeeding, pediatric, and geriatric patients)?
No information regarding the presence of Caplacizumab in human milk, effects on children being breastfed, or on milk production. However, the condition of the mother, developmental and health benefits of breastfeeding, as well as potential adverse effects on the breastfed child should be considered. Safety and effectiveness of Caplacizumab use in pediatric patients has not been established. Due to insufficiency of subjects over 65 years of age, safety and effectiveness in geriatric patients cannot be established. Since no formal studies have been conducted in patients with severe acute or chronic hepatic impairment under Caplacizumab treatment, considering the potential risk of bleeding, patients require close monitoring.
What is the cost of cablivi (caplacizumab-yhdp) injection online in India?
The cost of cablivi (caplacizumab-yhdp) injection in India varies as it is not locally marketed and must be imported. Pricing depends on supplier availability, import charges, and international currency fluctuations. For the latest price details, contact 24/7QualityMeds at +91 9967979080.
How to buy cablivi (caplacizumab-yhdp) injection online in India?
To buy cablivi (caplacizumab-yhdp) injection in India at a genuine price, reach out to 24/7QualityMeds. We help patients legally import the medicine with safe, reliable delivery and complete assistance throughout the process.
What are the key criteria for selecting a supplier?
While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.
